Peter Groenen currently heads the Translational Science Group at Idorsia Pharmaceuticals. Holding a PhD in molecular genetics he is extremely interested in the molecular aspects of disease and treatment. He received is MSc in Biochemistry and Physiology from the Radboud University, Nijmegen the Netherlands.
Before gaining his PhD in biomedical sciences at the Center for Human Genetics at the Gasthuisberg Medical Hospital, University of Leuven, Belgium he was a junior scientist at the National Institute for Health and Environmental Protection, Bilthoven the Netherlands and F. Hoffmann-La Roche AG, Basel Switzerland. Peter held several positions with increasing responsibility at Organon NV (part of Akzo Nobel), Schering-Plough and Merck Sharp & Dohme, Oss, the Netherlands.
Peter Groenen has authored or co-authored over 30 peer reviewed articles in diverse areas of genetics, bioinformatics and biomarkers. He led two large national public private partnership projects in the Netherlands on genomics in psychiatric disorders and bioinformatics.
He currently also serves as an editor of the recently launched journal “Digital Biomarkers” and serves as a core member of the DayOne initiative of the BaselAsrea.Swiss.